Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Blueprint Medicines Corporation (BPMC) stocks in Canada
Learn how to easily invest in Blueprint Medicines Corporation stocks.
Blueprint Medicines Corporation is a biotechnology business based in the US. Blueprint Medicines Corporation stocks (BPMC.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $90.82 – a decrease of 11.65% over the previous week. Blueprint Medicines Corporation employs 476 staff and has a trailing 12-month revenue of around $107.2 million.
How to buy shares in Blueprint Medicines Corporation
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – BPMC – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- Can I buy shares in Blueprint Medicines Corporation?
- Has coronavirus impacted Blueprint Medicines Corporation shares?
- Blueprint Medicines Corporation shares summary
- Compare share dealing platforms
- Is Blueprint Medicines Corporation stock a buy or sell?
- Blueprint Medicines Corporation performance over time
- Blueprint Medicines Corporation's financials
- How volatile are Blueprint Medicines Corporation shares?
- Does Blueprint Medicines Corporation pay a dividend?
- Other common questions
Blueprint Medicines Corporation stock price (NASDAQ:BPMC)Use our graph to track the performance of BPMC stocks over time.
Blueprint Medicines Corporation shares at a glance
|Latest market close||$68.91|
|52-week range||$74.75 - $117.86|
|50-day moving average||$102.61|
|200-day moving average||$96.16|
|Wall St. target price||$120.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.12|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Blueprint Medicines Corporation stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Blueprint Medicines Corporation price performance over time
|1 week (2022-01-14)||-11.65%|
|1 month (2021-12-22)||-36.57%|
|3 months (2021-10-22)||-32.63%|
|6 months (2021-07-22)||-19.31%|
|1 year (2021-01-22)||-32.01%|
|2 years (2020-01-22)||-1.30%|
|3 years (2019-01-22)||3.38%|
|5 years (2017-01-20)||113.28%|
Is Blueprint Medicines Corporation under- or over-valued?
Valuing Blueprint Medicines Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Blueprint Medicines Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Blueprint Medicines Corporation's EBITDA
Blueprint Medicines Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $345.2 million.
The EBITDA is a measure of a Blueprint Medicines Corporation's overall financial performance and is widely used to measure a its profitability.
Blueprint Medicines Corporation financials
|Revenue TTM||$107.2 million|
|Gross profit TTM||$466.5 million|
|Return on assets TTM||-16.96%|
|Return on equity TTM||-32.03%|
|Market capitalisation||$4.6 billion|
TTM: trailing 12 months
Blueprint Medicines Corporation share dividends
We're not expecting Blueprint Medicines Corporation to pay a dividend over the next 12 months.
Blueprint Medicines Corporation share price volatility
Over the last 12 months, Blueprint Medicines Corporation's shares have ranged in value from as little as $74.75 up to $117.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Blueprint Medicines Corporation's is 0.7172. This would suggest that Blueprint Medicines Corporation's shares are less volatile than average (for this exchange).
Blueprint Medicines Corporation overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. ; CStone Pharmaceuticals; Genentech, Inc. ; and F.
Stocks similar to Blueprint Medicines Corporation
Blueprint Medicines Corporation in the news
Sib Llc Buys FIGS Inc, Sells Blueprint Medicines Corp
Blueprint Medicines Elevates Two Talented Leaders to its Executive Team
Blueprint Medicines : Elevates Two Talented Leaders to its Executive Team - Form 8-K
Frequently asked questions
More guides on Finder
How to buy Aritzia stock in Canada
Steps to owning and managing Aritzia (ATZ) stock, with 24-hour and historical pricing before you buy.
CI Direct Trading review
Get low fees and access many different types of accounts, platforms and investments with this reputable online broker.
Hifi Finance (MFT) price prediction
Read our expert analysis on Hifi Finance and how the token will perform in the future.
Kusama (KSM) price prediction
Read our expert analysis on Kusama and how the token will perform in the future.
How to buy The Sandbox (SAND) in Canada
This guide provides step-by-step instructions on how to buy The Sandbox, lists some exchanges where you can get it and provides daily price data on SAND.
COVID testing stocks
We’ve rounded up stats on some of the most popular COVID testing stocks, along with information on how they compare and how to invest.
Shiba Inu (SHIB) price, history and performance
This guide explores the different ways of buying Shiba Inu on a cryptocurrency exchange as well as where you should store your cryptocurrency.
Baby Doge Coin (BABYDOGE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Baby Doge Coin, lists some exchanges where you can get it and provides daily price data on BABYDOGE.
Pendle (PENDLE) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Pendle, lists some exchanges where you can get it and provides daily price data on PENDLE.
Hempcoin (THC) price, chart, coin profile and news
This guide provides step-by-step instructions on how to buy Hempcoin, lists some exchanges where you can get it and provides daily price data on THC.